Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.
Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.
复制标题
AS04 佐剂疫苗针对人乳头瘤病毒 (HPV) 16 型和 18 型清除 HPV 感染的功效：哥斯达黎加疫苗试验和 PATRICIA 研究数据的汇总分析。
DOI：
10.1093/infdis/jiaa561
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Kreimer,
中科院分区：
文献类型：
--
作者：
Tota,JosephE;Struyf,Frank;Hildesheim,Allan;Gonzalez,Paula;Ryser,Martin;Herrero,Rolando;Schussler,John;Karkada,Naveen;Rodriguez,AnaCecilia;Folschweiller,Nicolas;Porras,Carolina;Schiffman,Mark;Schiller,JohnT;Quint,Wim;Kreimer,
临床试验数据和真实证据表明，针对16型和18型人乳头瘤病毒（AS04-HPV-16/18）的as04佐剂疫苗在初次性行为前接种的女性中，对3级或更高级别宫颈上皮内瘤变（不论类型）提供了近90%的保护。这种高功效不能完全用交叉保护来解释。虽然接种AS04-HPV-16/18疫苗不影响对流行感染的清除，但它可能加速对新获得性感染的清除。我们汇集了两项大规模随机对照试验的数据，以评估AS04-HPV-16/18疫苗对非靶向事件感染清除的功效。我们的分析结果并不表明在加速清除事件感染的影响。
Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.